The Medicines and Healthcare Regulatory Agency (MHRA) said on Thursday the risk associated with this type of blood clot is “very small” and that the public should continue to take up the vaccine when offered it. Out of 18.1 million doses administered up to and including March 24, the agency said it had identified 30 cases of rare blood clot events following use of the Oxford/AstraZeneca jab.
Of these, it said it had received 22 reports of cerebral venous sinus thrombosis and eight reports of other thrombosis events with low platelets. It comes less than two weeks after the EU drug regulator said the vaccine does not increase the overall incidence of blood clots following a similar scare.
Responding to the data, a member of the Joint Committee on Vaccination and Immunisation (JCVI) said taking up the vaccine was “by far the safest choice” at minimising risk of serious illness or death. Professor Adam Finn, from the University of Bristol, said: “The report states that these cases are being very carefully investigated to better understand whether or not they may have any causal relationship with vaccination.